Sara K. Peterson

Sara K. Peterson

Auto-generated profile, based on publicly available information

Sara K. Peterson

University of North Carolina at Chapel Hill 6 Curriculum in Bioinformatics and Computational Biology Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
JJJeffrey L Jensen
Jeffrey L Jensen
SPSara K Peterson
Sara K Peterson
MSMaria J Sambade
Maria J Sambade
JAJessica R Alley
Jessica R Alley
SYShawn Yu
Shawn Yu
BVBenjamin G Vincent
Benjamin G Vincent
Background: NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing NUTM1 fusion oncogenes, most commonly BRD4::NUTM1 . BRD4::NUTM1 recruits p300 to acetylate H3K27 forming expansive stretches of hyperacetylated chromatin called “megadomains” with the overexpression of corresponding oncogenes, including MYC . We hypothesized that transcriptional dysregulation caused by BRD4::NUTM1 would lead to the generation of cancer-specific antigens that could be therapeutically actionable. Methods: We integrated genomics, computational antigen prediction software, targeted immunopeptidomics using single-labeled and double-labeled peptide standards, and gain/loss-of-function genetic experiments on a panel of cell lines (N=5), a patient-derived xenograft, a tissue microarray (N=77), and patient samples from the Tempus AI Sequencing Database harboring evidence of NUTM1 fusions (N=165). We created an αPRAME 425 T-cell receptor (TCR) × SP34 αCD3 bispecific molecule modeled after brenetafusp, an αPRAME 425 TCR bispecific T-cell engager, as well as αPRAME 425 TCR T-cells based on anzutresgene autoleucel and we applied these products to NUT carcinoma cells in vitro . Results: We identified PRAME as the most commonly expressed cancer/testis antigen in patient samples harboring the three canonical NUT carcinoma fusions ( BRD4::NUTM1 , BRD3::NUTM1 , and NSD3::NUTM1 ). Additionally, 56% (43/77) of NUT carcinoma tissue microarray samples stained positive for PRAME. BRD4::NUTM1 expression in HEK 293T cells enhanced PRAME levels and BRD4::NUTM1 knockout in NUT carcinoma cells reduced PRAME levels. Immunopeptidomics detected more PRAME-derived human leukocyte antigen (HLA) ligands (N=9) than all other cancer/testis antigens combined (N=5). Targeted mass spectrometry detected the HLA-A*02:01/SLLQHLIGL (PRAME 425 ) epitope in 100% (4/4) of HLA-A*02+, PRAME+ NUT carcinoma samples at higher levels (>0.01 fM) than HLA-A*02:01/RLDQLLRHV (PRAME 312 ) or HLA-A*02:01/YLHARLREL (PRAME 462 ). The αPRAME 425 TCR × SP34 αCD3 bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells. Conclusions: PRAME is highly and frequently expressed in NUT carcinoma, and the most common oncoprotein causing NUT carcinoma, BRD4::NUTM1, contributes to these high PRAME levels. PRAME epitopes presented by HLA class I are a previously unrecognized therapeutic vulnerability for NUT carcinoma that warrants clinical trials testing PRAME-targeted immunotherapies in this neglected patient population.

17 February 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
AAAzar Alizadeh
Azar Alizadeh
JGJohn Graf
John Graf
MMMatthew J. Misner
Matthew J. Misner
ABAndrew A. Burns
Andrew A. Burns
Fiona GintyFiona Ginty
Fiona Ginty
LMLuca Marinelli
Luca Marinelli
Unraveling the complex associations between human phenotypes and molecular pathways can pave the way to improved health and performance, but faces a fundamental challenge: the measurable genes, proteins, and metabolites vastly outnumber the participants in even the largest studies, yielding spurious correlations. To address this, we developed PhenoMol, a bioinformatic framework that integrates comprehensive phenotypic data predictive of outcomes and reduces multi-omic dimensionality using graph theory constrained by prior biological knowledge. This approach generates biologically informed “expression circuits” to identify causal patterns. Applied to a deeply characterized healthy cohort, PhenoMol successfully predicted elite physical performance and outperformed regression models lacking network-based dimensionality reduction. Designed to be versatile and generalizable, PhenoMol enables studies across small and large populations to predict wellness, performance, and disease outcomes. The software is openly available to support future research in health, disease, and performance optimization.

12 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JJJeffrey L. Jensen
Jeffrey L. Jensen
SPSara K. Peterson
Sara K. Peterson
MSMaria Sambade
Maria Sambade
JAJessica R. Alley
Jessica R. Alley
SYShawn Yu
Shawn Yu
BVBenjamin G. Vincent
Benjamin G. Vincent
Background: NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing NUTM1 fusion oncogenes, most commonly BRD4::NUTM1 . BRD4::NUTM1 recruits p300 to acetylate H3K27 forming expansive stretches of hyperacetylated chromatin called “megadomains” with the overexpression of corresponding oncogenes, including MYC . We hypothesized that transcriptional dysregulation caused by BRD4::NUTM1 would lead to the generation of cancer-specific antigens that could be therapeutically actionable. Methods: We integrated genomics, computational antigen prediction software, targeted immunopeptidomics using single- and double-labeled peptide standards, and gain/loss-of-function genetic experiments on a panel of cell lines (N=5), a patient derived xenograft, a tissue microarray (N=77), and patient samples from the Tempus AI Sequencing Database harboring evidence of NUTM1 fusions (N=165). We created an αPRAME 425 T-cell receptor x SP34 αCD3 bispecific molecule modeled after brenetafusp, an αPRAME 425 T-cell receptor bispecific T-cell engager, as well as αPRAME 425 TCR T-cells based on anzutresgene autoleucel and we applied these products to NUT carcinoma cells in vitro . Results: We identified PRAME as the most commonly expressed cancer/testis antigen in patient samples harboring the three canonical NUT carcinoma fusions ( BRD4::NUTM1 , BRD3::NUTM1 , and NSD3::NUTM1 ). Additionally, 56% (43/77) of NUT carcinoma tissue microarray samples stained positive for PRAME. BRD4::NUTM1 expression in HEK 293T cells enhanced PRAME levels and BRD4::NUTM1 knockout in NUT carcinoma cells reduced PRAME levels. Immunopeptidomics detected more PRAME-derived HLA ligands (N=9) than all other cancer/testis antigens combined (N=5). Targeted mass spectrometry detected the HLA-A*02:01/SLLQHLIGL (PRAME 425 ) epitope in 100% (4/4) of HLA-A*02+, PRAME+ NUT carcinoma samples at higher levels (>0.01 fM) than HLA-A*02:01/RLDQLLRHV (PRAME 312 ) or HLA-A*02:01/YLHARLREL (PRAME 462 ). The αPRAME 425 T-cell receptor x SP34 αCD3 bispecific molecule and αPRAME 425 TCR T-cells each exhibited potent, T-cell mediated cytotoxicity against PRAME + NUT carcinoma cells. Conclusions: PRAME is highly and frequently expressed in NUT carcinoma and the most common oncoprotein causing NUT carcinoma, BRD4::NUTM1, contributes to these high PRAME levels. PRAME epitopes presented by HLA Class I are a previously unrecognized therapeutic vulnerability for NUT carcinoma that warrant clinical trials testing PRAME targeted immunotherapies in this neglected patient population. What is already known on this topic: NUT carcinoma is a devastating malignancy that is recalcitrant to cytotoxic chemotherapy, T-cell checkpoint blockade, and targeted therapies in the form of bromodomain inhibitors. What this study adds: NUT carcinoma tumors are high in the cancer/testis gene PRAME . The oncogene most commonly causing NUT carcinoma, BRD4::NUTM1 , contributes to these high levels. NUT carcinoma cells present PRAME epitopes on HLA Class I molecules and are susceptible to PRAME-directed, T-cell mediated cytotoxicity. How this study might affect research, practice or policy: Our results argue for phase I/II clinical trials testing PRAME immunotherapies like brenetafusp or anzutresgene autoleucel in PRAME + NUT carcinoma patients. Graphical

10 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SPSara K. Peterson
Sara K. Peterson
AMA. McCauley Massie
A. McCauley Massie
ARAlex Rubinsteyn
Alex Rubinsteyn
JWJeremy R. Wang
Jeremy R. Wang
IDIan J. Davis
Ian J. Davis
Microsatellites are abundant genomic elements that contribute to genetic diversity and disease-associated regulatory variation. Although long-read sequencing enables accurate resolution of repetitive regions, computational methods for fully resolved microsatellite genotyping remain limited. Here, we introduce variant motif where (vmwhere), a computational framework for identifying, genotyping, decomposing, and visualizing complex tetrameric microsatellites from long-read sequencing data. Using simulated error-free reads, vmwhere accurately measures several genotyping metrics, including allele length, repeat length, maximum consecutive repeat length, and motif density. Applied to long-read whole-genome sequencing data, vmwhere identified sequence interruptions, motif-specific differences in repeat architecture, and ancestry-associated allele variation, including long repeat alleles that exceed short-read sequencing limitations. We applied vmwhere to GGAA microsatellites in Ewing sarcoma, an aggressive pediatric cancer driven by EWS-FLI1 fusion oncoprotein, which binds to microsatellites and remodels chromatin. Genome-wide integration of long-read-defined microsatellite architecture with chromatin accessibility and EWS-FLI1 binding revealed that GGAA repeat structure was associated with chromatin state, with longer consecutive repeat microsatellites exhibiting increased EWS-FLI1 binding and chromatin accessibility. Cell line–specific expansions and contractions of GGAA microsatellite repeat length were associated with gains and losses of chromatin accessibility. Further, we identified haplotype-specific chromatin states, with preferential binding and accessibility at longer alleles. Together, these results establish vmwhere as a scalable framework for resolving population-level microsatellite variation and linking repeat architecture to chromatin state. Repeat structure and length characteristics provides insights into genotype–function relationships at microsatellite repeats in cancer.

30 October 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
JSJustin R. Sperlazza
Justin R. Sperlazza
KFKevin C. Field
Kevin C. Field
CMCaitlyn McComb
Caitlyn McComb
ELElisa Landoni
Elisa Landoni
SPSara K. Peterson
Sara K. Peterson
IDIan J. Davis
Ian J. Davis
Adoptive cellular therapies depend on the adequate expression of target antigens on tumors. The disialoganglioside GD2, a target of chimeric antigen receptor (CAR) T cells (GD2.CAR T cells) and monoclonal antibodies, is variably expressed in Ewing sarcoma and osteosarcoma. We investigated the ability of chromatin-directed small molecules to enhance tumor GD2 and sensitize tumors to GD2.CAR T cells. Although the EZH2 inhibitor tazemetostat increased GD2 levels in culture and in xenografted mice, tazemetostat treatment was unable to maintain sufficient tumor GD2 levels necessary to enable tumor control in a metastatic xenograft model. We performed a screen of chromatin-directed small molecules to identify additional compounds capable of regulating tumor GD2 and identified multiple compounds, including the HDAC inhibitor entinostat and the DOT1L inhibitor pinometostat. Both compounds greatly enhanced tumor GD2 expression by tazemetostat in culture but did not limit CAR T-cell activity. In multiple xenograft models, the combination of tazemetostat and entinostat resulted in enhanced tumor GD2 expression and led to long-term tumor control by GD2.CAR T cells. These data offer preclinical support for the incorporation of chromatin-directed inhibitors into ongoing CAR T-cell trials for Ewing sarcoma and osteosarcoma.